Cyclin A in nonfunctioning pituitary adenomas.
Cyclin A
Invasion
Nonfunctioning pituitary adenomas
Proliferation
Tumorigenesis
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
15
04
2020
accepted:
24
06
2020
pubmed:
6
7
2020
medline:
22
6
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Assess cyclin A in nonfunctioning pituitary adenomas (NFPA) and compare its expression in non-invasive and non-proliferative tumors with invasive and proliferative tumors (12× higher risk of recurrence). Quantitative real time polymerase chain reaction to analyze cyclin A using normal pituitary gland as reference. Fold change (FC) > 1 was considered as increased. Tumor invasion was based on Knosp criteria (grades 3-4 considered invasive) and proliferation on the presence of at least two of three criteria: Ki-67 ≥ 3%; mitoses > 2/10; positive p53. Both groups were compared with Mann-Whitney test considering p value < 0.05 as statistically significant. Thirty-one patients with NFPA were included. Tumors were mainly of gonadotrophic origin (74.2%), followed by corticotrophic (19.4%) and lactotrophic (3.2%) origins and null-cell adenomas (3.2%). Median tumor diameter was 3.5 cm (1.8-8.0) and Ki-67 was 3.0% (0.3-11%). Sixteen patients had tumors classified as non-invasive and non-proliferative and 15 as invasive and proliferative. Median FC was 0.31 in all tumors (0.13-1.94). Cyclin A was not related to invasion or proliferation (FC 0.41 in non-invasive and non-proliferative tumors and FC 0.30 in invasive and proliferative tumors; p = 0.968). Four (12.9%) patients had tumors that exhibited increased cyclin A [median FC of 1.04 (1.02-1.94)]-three of gonadotrophic origin and one null-cell adenoma, with two tumors classified as non-invasive and non-proliferative and two tumors classified as invasive and proliferative. Median tumor diameter in these samples was 3.4 cm (2.4-3.6) and Ki-67 was 5.1% (2-11%). Cyclin A was increased in a minority of NFPA and does not seem to be related to invasion or proliferation.
Identifiants
pubmed: 32621052
doi: 10.1007/s12020-020-02402-5
pii: 10.1007/s12020-020-02402-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Cyclin A
0
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-387Références
M.B.S. Lopes, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 134(4), 521–535 (2017). https://doi.org/10.1007/s00401-017-1769-8
doi: 10.1007/s00401-017-1769-8
pubmed: 28821944
S. Melmed, Pituitary tumors. Endocrinol. Metab. Clin. N. Am. 44(1), 1–9 (2015). https://doi.org/10.1016/j.ecl.2014.11.004
doi: 10.1016/j.ecl.2014.11.004
Y. Greenman, N. Stern, Non-functioning pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 625–638 (2009). https://doi.org/10.1016/j.beem.2009.05.005
doi: 10.1016/j.beem.2009.05.005
pubmed: 19945027
H. Buurman, W. Saeger, Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur. J. Endocrinol. 154(5), 753–758 (2006). https://doi.org/10.1530/eje.1.02107
doi: 10.1530/eje.1.02107
pubmed: 16645024
W. Saeger, D.K. Ludecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156(2), 203–216 (2007). https://doi.org/10.1530/eje.1.02326
doi: 10.1530/eje.1.02326
pubmed: 17287410
R.V. Lloyd, O.R., G. Klöppel, J. Rosai. WHO Classification of Tumours of Endocrine Organs, 4th edn. (IARC Press, Lyon, 2017).
J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357(9254), 425–431 (2001)
doi: 10.1016/S0140-6736(00)04006-X
D.S. Olsson, B.A. Bengtsson, Hypopituitarism-needs modern individualized treatment. Endocrine 56(1), 1–3 (2017). https://doi.org/10.1007/s12020-016-1211-3
doi: 10.1007/s12020-016-1211-3
pubmed: 28004235
J.R. Anderson, N. Antoun, N. Burnet, K. Chatterjee, O. Edwards, J.D. Pickard, N. Sarkies, Neurology of the pituitary gland. J. Neurol. Neurosurg. Psychiatry 66(6), 703–721 (1999)
doi: 10.1136/jnnp.66.6.703
L.E. Wildemberg, A. Glezer, M.D. Bronstein, M.R. Gadelha, Apoplexy in nonfunctioning pituitary adenomas. Pituitary 21(2), 138–144 (2018). https://doi.org/10.1007/s11102-018-0870-x
doi: 10.1007/s11102-018-0870-x
pubmed: 29383476
L.N. Vieira, C.L. Boguszewski, L.A. Araujo, M.D. Bronstein, P.A. Miranda, N.R. Musolino, L.A. Naves, L. Vilar, A.J. Ribeiro-Oliveira, M.R. Gadelha, A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch. Endocrinol. Metab. 60(4), 374–390 (2016). https://doi.org/10.1590/2359-3997000000179
doi: 10.1590/2359-3997000000179
K. Boelaert, N.J. Gittoes, Radiotherapy for non-functioning pituitary adenomas. Eur. J. Endocrinol. 144(6), 569–575 (2001)
doi: 10.1530/eje.0.1440569
Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4), 333–342 (2012). https://doi.org/10.1159/000339823
doi: 10.1159/000339823
pubmed: 22687984
pmcid: 22687984
B.W. Scheithauer, K.T. Kovacs, E.R. Laws Jr, R.V. Randall, Pathology of invasive pituitary tumors with special reference to functional classification. J. Neurosurg. 65(6), 733–744 (1986). https://doi.org/10.3171/jns.1986.65.6.0733
doi: 10.3171/jns.1986.65.6.0733
pubmed: 3095506
pmcid: 3095506
L. Kasuki, G. Raverot. Definition and diagnosis of aggressive pituitary tumors. Rev. Endocr. Metab. Disord. (2019). https://doi.org/10.1007/s11154-019-09531-x
M.R. Gadelha, G. Trivellin, L.C. Hernandez Ramirez, M. Korbonits, Genetics of pituitary adenomas. Front. Horm. Res. 41, 111–140 (2013). https://doi.org/10.1159/000345673
doi: 10.1159/000345673
pubmed: 23652674
R. Yu, S. Melmed, Pathogenesis of pituitary tumors. Prog. Brain Res. 182, 207–227 (2010). https://doi.org/10.1016/S0079-6123(10)82009-6
doi: 10.1016/S0079-6123(10)82009-6
pubmed: 20541667
S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7(5), 257–266 (2011). https://doi.org/10.1038/nrendo.2011.40
doi: 10.1038/nrendo.2011.40
pubmed: 21423242
V. Quereda, M. Malumbres, Cell cycle control of pituitary development and disease. J. Mol. Endocrinol. 42(2), 75–86 (2009). https://doi.org/10.1677/JME-08-0146
doi: 10.1677/JME-08-0146
pubmed: 18987159
C. Desdouets, G. Matesic, C.A. Molina, N.S. Foulkes, P. Sassone-Corsi, C. Brechot, J. Sobczak-Thepot, Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. Mol. Cell. Biol. 15(6), 3301–3309 (1995). https://doi.org/10.1128/mcb.15.6.3301
doi: 10.1128/mcb.15.6.3301
pubmed: 7760825
pmcid: 230563
A. Loukil, C.T. Cheung, N. Bendris, B. Lemmers, M. Peter, J.M. Blanchard, Cyclin A2: at the crossroads of cell cycle and cell invasion. World J. Biol. Chem. 6(4), 346–350 (2015). https://doi.org/10.4331/wjbc.v6.i4.346
doi: 10.4331/wjbc.v6.i4.346
pubmed: 26629317
pmcid: 4657123
C. Miao, Z. Wang, J. Yang, J. Li, X. Gao, Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression. Oncol. Lett. 10(3), 1716–1720 (2015). https://doi.org/10.3892/ol.2015.3474
doi: 10.3892/ol.2015.3474
pubmed: 26622738
pmcid: 4533753
C.H. Yam, T.K. Fung, R.Y. Poon, Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci. 59(8), 1317–1326 (2002). https://doi.org/10.1007/s00018-002-8510-y
doi: 10.1007/s00018-002-8510-y
pubmed: 12363035
S. Diederichs, N. Baumer, P. Ji, S.K. Metzelder, G.E. Idos, T. Cauvet, W. Wang, M. Moller, S. Pierschalski, J. Gromoll, M.G. Schrader, H.P. Koeffler, W.E. Berdel, H. Serve, C. Muller-Tidow, Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J. Biol. Chem. 279(32), 33727–33741 (2004). https://doi.org/10.1074/jbc.M401708200
doi: 10.1074/jbc.M401708200
pubmed: 15159402
H.E. Turner, Z. Nagy, N. Sullivan, M.M. Esiri, J.A. Wass, Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. 53(3), 337–344 (2000)
doi: 10.1046/j.1365-2265.2000.01088.x
B. Henglein, X. Chenivesse, J. Wang, D. Eick, C. Brechot, Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc. Natl Acad. Sci. USA 91(12), 5490–5494 (1994)
doi: 10.1073/pnas.91.12.5490
A.R. Rosenberg, F. Zindy, F. Le Deist, H. Mouly, P. Metezeau, C. Brechot, E. Lamas, Overexpression of human cyclin A advances entry into S phase. Oncogene 10(8), 1501–1509 (1995)
pubmed: 7731704
K. Allan, R.C. Jordan, L.C. Ang, M. Taylor, B. Young, Overexpression of cyclin A and cyclin B1 proteins in astrocytomas. Arch. Pathol. Lab. Med. 124(2), 216–220 (2000). https://doi.org/10.1043/0003-9985(2000)1242.0.CO;2
doi: 10.1043/0003-9985(2000)1242.0.CO;2
pubmed: 10656729
M. Furihata, T. Ishikawa, A. Inoue, C. Yoshikawa, H. Sonobe, Y. Ohtsuki, K. Araki, S. Ogoshi, Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 2(10), 1781–1785 (1996)
pubmed: 9816130
R.D. Mashal, S. Lester, C. Corless, J.P. Richie, R. Chandra, K.J. Propert, A. Dutta, Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56(18), 4159–4163 (1996)
pubmed: 8797586
J. Kushner, G. Bradley, B. Young, R.C. Jordan, Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J. Oral Pathol. Med. 28(2), 77–81 (1999). https://doi.org/10.1111/j.1600-0714.1999.tb02000.x
doi: 10.1111/j.1600-0714.1999.tb02000.x
pubmed: 9950254
J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot, A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin,Members of HYPOPRONOS, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013). https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
pmcid: 23400299
R. Zahr, M. Fleseriu, Updates in diagnosis and treatment of acromegaly. Eur. Endocrinol. 14(2), 57–61 (2018). https://doi.org/10.17925/EE.2018.14.2.57
doi: 10.17925/EE.2018.14.2.57
pubmed: 30349595
pmcid: 6182922
L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008). https://doi.org/10.1210/jc.2008-0125
doi: 10.1210/jc.2008-0125
pubmed: 18334580
pmcid: 2386281
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, S. Endocrine, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011). https://doi.org/10.1210/jc.2010-1692
doi: 10.1210/jc.2010-1692
pubmed: 21296991
E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993). https://doi.org/10.1227/00006123-199310000-00008 . discussion 617-618
doi: 10.1227/00006123-199310000-00008
pubmed: 8232800
P. Lundin, F. Pedersen, Volume of pituitary macroadenomas: assessment by MRI. J. Comput. Assist. Tomogr. 16(4), 519–528 (1992). https://doi.org/10.1097/00004728-199207000-00004
doi: 10.1097/00004728-199207000-00004
pubmed: 1629407
H. Nishioka, N. Inoshita, O. Mete, S.L. Asa, K. Hayashi, A. Takeshita, N. Fukuhara, M. Yamaguchi-Okada, Y. Takeuchi, S. Yamada, The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr. Pathol. 26(4), 349–355 (2015). https://doi.org/10.1007/s12022-015-9398-z
doi: 10.1007/s12022-015-9398-z
pubmed: 26481628
M.E. Torregrosa-Quesada, A. Garcia-Martinez, S. Silva-Ortega, S. Martinez-Lopez, R. Camara, C. Fajardo, C. Lamas, I. Aranda, A. Pico. How valuable is the RT-qPCR of pituitary-specific transcription factors for identifying pituitary neuroendocrine tumor subtypes according to the new WHO 2017 criteria? Cancers 11(12), (2019). https://doi.org/10.3390/cancers11121990
A. de Almeida Verdolin, E.B. Lamback, N. Ventura, A. Guasti, P.J. da Mata Pereira, M.R. Gadelha, L. Chimelli. Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience. Endocrine (2019). https://doi.org/10.1007/s12020-019-02149-8
K.R. Normann, K.A.B. Oystese, J.P. Berg, T. Lekva, J. Berg-Johnsen, J. Bollerslev, N.C. Olarescu, Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol. Cell. Endocrinol. 437, 183–189 (2016). https://doi.org/10.1016/j.mce.2016.08.030
doi: 10.1016/j.mce.2016.08.030
pubmed: 27561203
K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4), 402–408 (2001). https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
M. Musat, V.V. Vax, N. Borboli, M. Gueorguiev, S. Bonner, M. Korbonits, A.B. Grossman, Cell cycle dysregulation in pituitary oncogenesis. Front. Horm. Res. 32, 34–62 (2004). https://doi.org/10.1159/000079037
doi: 10.1159/000079037
pubmed: 15281339
H. Nakabayashi, I. Sunada, M. Hara, Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J. Histochem. Cytochem. 49(9), 1193–1194 (2001). https://doi.org/10.1177/002215540104900916
doi: 10.1177/002215540104900916
pubmed: 11511691
G. O’Hurley, E. Sjostedt, A. Rahman, B. Li, C. Kampf, F. Ponten, W.M. Gallagher, C. Lindskog, Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol. Oncol. 8(4), 783–798 (2014). https://doi.org/10.1016/j.molonc.2014.03.008
doi: 10.1016/j.molonc.2014.03.008
pubmed: 24725481
pmcid: 5528533
H.P. Sinn, A. Schneeweiss, M. Keller, K. Schlombs, M. Laible, J. Seitz, S. Lakis, E. Veltrup, P. Altevogt, S. Eidt, R.M. Wirtz, F. Marme, Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer 17(1), 124 (2017). https://doi.org/10.1186/s12885-017-3111-1
doi: 10.1186/s12885-017-3111-1
pubmed: 28193205
pmcid: 5307758
C. Ramirez, S. Cheng, G. Vargas, S.L. Asa, S. Ezzat, B. Gonzalez, L. Cabrera, G. Guinto, M. Mercado, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J. Clin. Endocrinol. Metab. 97(5), 1745–1751 (2012). https://doi.org/10.1210/jc.2011-3163
doi: 10.1210/jc.2011-3163
pubmed: 22419713
I. Kalaszczynska, Y. Geng, T. Iino, S. Mizuno, Y. Choi, I. Kondratiuk, D.P. Silver, D.J. Wolgemuth, K. Akashi, P. Sicinski, Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell 138(2), 352–365 (2009). https://doi.org/10.1016/j.cell.2009.04.062
doi: 10.1016/j.cell.2009.04.062
pubmed: 19592082
pmcid: 2745999
F. Traganos, Cycling without cyclins. Cell Cycle 3(1), 32–34 (2004)
doi: 10.4161/cc.3.1.608
S. Jordan, K. Lidhar, M. Korbonits, D.G. Lowe, A.B. Grossman, D. Cyclin, and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 143(1), R1–R6 (2000). https://doi.org/10.1530/eje.0.143r001
doi: 10.1530/eje.0.143r001
pubmed: 10870044
N.A. Hibberts, D.J. Simpson, J.E. Bicknell, J.C. Broome, P.R. Hoban, R.N. Clayton, W.E. Farrell, Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5(8), 2133–2139 (1999)
pubmed: 10473097